Alector, Inc. (Nasdaq: ALEC), a biotechnology company headquartered in South San Francisco, California, has announced the pricing of an underwritten public offering. The company entered into an underwriting agreement with Morgan Stanley & Co. LLC and BTIG, LLC on October 15, 2026.
Under the terms of the agreement, Alector is selling 36,600,000 shares of its common stock. The shares are priced at $2.05 per share. This price represents a premium of approximately 7.3% over the closing price of the stock on October 15, 2026.
The gross proceeds from the offering are expected to total $75,030,000.00 before deducting underwriting discounts and commissions and other estimated offering expenses. All shares are being sold by Alector. The offering is expected to close on or about October 19, 2026, subject to the satisfaction of customary closing conditions.
Alector anticipates using the net proceeds from the financing for general corporate purposes. These purposes may include research and development, manufacturing of product candidates, working capital, capital expenditures, other corporate expenses, and potential acquisitions of complementary products, technologies, or businesses.
The offering is being conducted pursuant to a shelf registration statement previously filed with and declared effective by the Securities and Exchange Commission (SEC). A prospectus supplement related to the offering is available on the SEC’s website.
